- Report
- March 2025
- 145 Pages
Global
From €2686EUR$2,999USD£2,290GBP
- Report
- December 2024
- 305 Pages
Global
From €4434EUR$4,950USD£3,779GBP
- Report
- May 2025
- 189 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 138 Pages
Global
From €2686EUR$2,999USD£2,290GBP
- Report
- December 2024
- 105 Pages
Global
From €5329EUR$5,950USD£4,543GBP
- Report
- August 2024
- 120 Pages
Global
From €5329EUR$5,950USD£4,543GBP
- Report
- April 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- February 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- February 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- June 2025
- 297 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- March 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- January 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- January 2025
- 175 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- December 2024
- 150 Pages
Global
From €3359EUR$3,750USD£2,863GBP
- Report
- July 2024
- 100 Pages
Global
From €3359EUR$3,750USD£2,863GBP
- Report
- December 2024
- 200 Pages
Global
From €3359EUR$3,750USD£2,863GBP
- Report
- January 2025
- 142 Pages
Global
From €3538EUR$3,950USD£3,016GBP
- Report
- August 2024
- 200 Pages
Global
From €3583EUR$4,000USD£3,054GBP
- Report
- March 2025
Global
From €6718EUR$7,500USD£5,726GBP
- Report
- July 2024
- 96 Pages
Global
From €4031EUR$4,500USD£3,436GBP

Transcatheter Aortic Valve Implantation (TAVI) is a minimally invasive procedure used to treat aortic valve stenosis, a condition in which the aortic valve does not open properly. During the procedure, a catheter is inserted through a small incision in the groin and guided to the heart. A replacement valve is then inserted through the catheter and implanted in the aortic valve. TAVI is a relatively new procedure, having been approved by the FDA in 2011, and is an alternative to traditional open-heart surgery.
TAVI is a rapidly growing market within the cardiovascular devices industry. It is a less invasive procedure than open-heart surgery, and is associated with fewer complications and shorter recovery times. It is also more cost-effective than traditional surgery, making it an attractive option for many patients.
Some of the major companies in the TAVI market include Edwards Lifesciences, Medtronic, Boston Scientific, and Abbott. Show Less Read more